Revealing a steroid receptor ligand as a unique PPARγ agonist

被引:0
|
作者
Shengchen Lin
Ying Han
Yuzhe Shi
Hui Rong
Songyang Zheng
Shikan Jin
Shu-Yong Lin
Sheng-Cai Lin
Yong Li
机构
[1] State Key Laboratory for Cellular Stress Biology,Department of Pharmaceutical Sciences
[2] School of Life Sciences,undefined
[3] Xiamen University,undefined
[4] Center for Pharmacogenetics,undefined
[5] University of Pittsburgh,undefined
来源
Cell Research | 2012年 / 22卷
关键词
PPARγ; nuclear receptor; diabetes; crystal structure; steroid compound;
D O I
暂无
中图分类号
学科分类号
摘要
Peroxisome proliferator-activated receptor gamma (PPARγ) regulates metabolic homeostasis and is a molecular target for anti-diabetic drugs. We report here the identification of a steroid receptor ligand, RU-486, as an unexpected PPARγ agonist, thereby uncovering a novel signaling route for this steroid drug. Similar to rosiglitazone, RU-486 modulates the expression of key PPARγ target genes and promotes adipocyte differentiation, but with a lower adipogenic activity. Structural and functional studies of receptor-ligand interactions reveal the molecular basis for a unique binding mode for RU-486 in the PPARγ ligand-binding pocket with distinctive properties and epitopes, providing the molecular mechanisms for the discrimination of RU-486 from thiazolidinediones (TZDs) drugs. Our findings together indicate that steroid compounds may represent an alternative approach for designing non-TZD PPARγ ligands in the treatment of insulin resistance.
引用
收藏
页码:746 / 756
页数:10
相关论文
共 50 条
  • [1] Revealing a steroid receptor ligand as a unique PPARγ agonist
    Lin, Shengchen
    Han, Ying
    Shi, Yuzhe
    Rong, Hui
    Zheng, Songyang
    Jin, Shikan
    Lin, Shu-Yong
    Lin, Sheng-Cai
    Li, Yong
    [J]. CELL RESEARCH, 2012, 22 (04) : 746 - 756
  • [2] Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition
    Tian, Siyu
    Wang, Rui
    Chen, Shuming
    He, Jialing
    Zheng, Weili
    Li, Yong
    [J]. MOLECULES, 2021, 26 (19):
  • [3] Structure of the PPARα and -γ ligand binding domain in complex with AZ 242;: Ligand selectivity and agonist activation in the PPAR family
    Cronet, P
    Petersen, JFW
    Folmer, R
    Blomberg, N
    Sjöblom, K
    Karlsson, U
    Lindstedt, EL
    Bamberg, K
    [J]. STRUCTURE, 2001, 9 (08) : 699 - 706
  • [4] Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
    Unni Syversen
    Astrid K Stunes
    Björn I Gustafsson
    Karl J Obrant
    Lars Nordsletten
    Rolf Berge
    Liv Thommesen
    Janne E Reseland
    [J]. BMC Endocrine Disorders, 9
  • [5] Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
    Syversen, Unni
    Stunes, Astrid K.
    Gustafsson, Bjorn I.
    Obrant, Karl J.
    Nordsletten, Lars
    Berge, Rolf
    Thommesen, Liv
    Reseland, Janne E.
    [J]. BMC ENDOCRINE DISORDERS, 2009, 9
  • [6] UNIQUE STEROID CONGENERS FOR RECEPTOR STUDIES
    OJASOO, T
    RAYNAUD, JP
    [J]. CANCER RESEARCH, 1978, 38 (11) : 4186 - 4198
  • [7] Ligand entry pathways in the ligand binding domain of PPARγ receptor
    Aci-Seche, Samia
    Genest, Monique
    Garnier, Norbert
    [J]. FEBS LETTERS, 2011, 585 (16): : 2599 - 2603
  • [8] Dual agonist of PPAR α/γ:: Unique potential for the better management of Syndrome X
    Chakrabarti, R
    Das, S
    Datla, S
    Babu, R
    Hegde, P
    Hiriyan, J
    Suryaprakash, R
    [J]. DIABETES, 2003, 52 : A113 - A113
  • [9] PPAR gamma is a representative of the nuclear steroid receptor family
    Kononenko, I., V
    Smirnova, O. M.
    [J]. DIABETES MELLITUS, 2005, 8 (02): : 74 - 77
  • [10] Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-α receptor agonist GW7647
    Russo, Roberto
    LoVerme, Jesse
    La Rana, Giovanna
    D'Agostino, Giuseppe
    Sasso, Oscar
    Calignano, Antonio
    Piomelli, Daniele
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 566 (1-3) : 117 - 119